Table 1.
Comparison of baseline demographical parameters between DAPA-HF, EMPEROR-Reduced and VICTORIA trial.
| Characteristics (intervention arm) | DAPA-HF (n=4744) | EMPEROR-Reduced (n=3730) | VICTORIA (n=5050) |
|---|---|---|---|
| Patients included (n) | 2373 | 1863 | 2526 |
| Study medication | Dapagliflozin | Empagliflozin | Vericiguat |
| Administration timeframe | Once/daily | Once/daily | Once/daily |
| Comparator | Placebo | Placebo | placebo |
| Follow-up (months) | 18.2 | 16.0 | 10.8 |
| Age (y) | 66.2 | 67.2 | 67.5 |
| Female (%) | 23.8 | 23.5 | 24.0 |
| NYHA functional class III (%) | 31.5 | 24.4 | 40 |
| NYHA functional class IV (%) | 0.8 | 0.5 | 1.4 |
| CAD (%) | 55.5 | 52.8 | 59.8 |
| LVEF (%) | 31.2 | 27.7 | 29 |
| NT-proBNP (ng/L) | 1428 | 1887 | 2803 |
| eGFR (mL/minute/1.73 m2) | 66.0 | 61.8 | 61.3 |
| Atrial fibrillation (%) | 38.6 | 35.6 | 43.5 |
| Previous HFH (%) | 47.4 | 31.0 | 84.2 |
| IV diuretic for HF (no HFH) | NA | NA | 15.8 |
| Sacubitril/valsartan (%) | 10.5 | 18.3 | 14.3 |
| ICD (%) | 26.2 | 31.0 | 27.6 |
| CRT (%) | 8 | 11.8 | 14.7 |
Main demographic characteristics of the intervention arms of DAPA-HF study, EMPEROR-Reduced study and VICTORIA trial.7–9
CAD, coronary artery disease; CRT, cardiac resynchronization therapy; eGFR, estimated glomerular filtration rate; HFH, heart failure hospitalization; ICD, implantable cardioverter defibrillator; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association.